Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Lebrikizumab
Lebrikizumab is a substance that reduces skin inflammation by targeting a specific immune protein, used for moderate-to-severe eczema.
Mometasone
Mometasone is a corticosteroid substance that reduces inflammation for allergic nasal symptoms and inflammatory skin conditions.
Mometasone Furoate
Mometasone furoate is a corticosteroid that reduces inflammation and relieves symptoms of allergic nasal conditions and inflammatory skin problems.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Pneumocare
Jambes, Belgium
Universitair Ziekenhuis Gent
Otorhinolaryngology Department
Ledeberg, Belgium
Cliniques Universitaires Saint-Luc
Otorhinolaryngology Department
Sint-Stevens-Woluwe, Belgium

Sponsor: Eli Lilly & Co.
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.